Innovative MedTech Files 8-K: Agreements, Obligations, Equity Sales

TL;DR

IMTH filed an 8-K detailing new agreements, financial obligations, and equity sales.

AI Summary

Innovative MedTech, Inc. entered into a material definitive agreement on August 6, 2025. The company also incurred a direct financial obligation or an off-balance sheet arrangement. Additionally, the filing indicates unregistered sales of equity securities and includes financial statements and exhibits.

Why It Matters

This 8-K filing signals significant corporate actions by Innovative MedTech, Inc., including new financial commitments and equity transactions that could impact its financial structure and shareholder value.

Risk Assessment

Risk Level: medium — The filing involves material definitive agreements, financial obligations, and unregistered equity sales, which can introduce financial and operational risks.

Key Players & Entities

• Innovative MedTech, Inc. (company) — Registrant
• August 6, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $97,750 — missory note in the principal amount of $97,750 (the " Note ") for a purchase price of
• $85,000 — (the " Note ") for a purchase price of $85,000 (the " Transaction "). The Transaction
• $3,500 — ut August 6, 2025, pursuant to the SPA, $3,500 was retained by Labrys from the purchas
• $4,500 — from the purchase price for legal fees, $4,500 was paid to HCC Securities Group, Inc.,
• $77,000 — er, the Company received net funding of $77,000, and the Note was issued to Labrys. Th
• $54,740 b — cipal amount at issuance, shall be paid $54,740 by February 4, 2026, and $9,123.33 by the
• $9,123.33 b — e paid $54,740 by February 4, 2026, and $9,123.33 by the 4 th day of each month thereafter,
• $1,500 — nally, the holder is entitled to deduct $1,500 from the conversion amount in each note

Filing Documents

• imth_8k.htm (8-K) — 28KB
• imth_ex101.htm (EX-10.1) — 150KB
• imth_ex102.htm (EX-10.2) — 116KB
• 0001477932-25-005597.txt ( ) — 473KB
• imth-20250806.xsd (EX-101.SCH) — 5KB
• imth-20250806_lab.xml (EX-101.LAB) — 13KB
• imth-20250806_cal.xml (EX-101.CAL) — 1KB
• imth-20250806_pre.xml (EX-101.PRE) — 8KB
• imth-20250806_def.xml (EX-101.DEF) — 2KB
• imth_8k_htm.xml (XML) — 3KB

01. Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement. Effective as of August 6, 2025, Innovative MedTech, Inc. (the " Company ") entered into a securities purchase agreement (the " SPA ") with Labrys Fund II, L.P., a Delaware limited partnership (" Labrys "), pursuant to which the Company sold, and Labrys purchased, a convertible promissory note in the principal amount of $97,750 (the " Note ") for a purchase price of $85,000 (the " Transaction "). The Transaction was funded by Labrys and closed on August 6, 2025, and on or about August 6, 2025, pursuant to the SPA, $3,500 was retained by Labrys from the purchase price for legal fees, $4,500 was paid to HCC Securities Group, Inc., a registered broker-dealer, the Company received net funding of $77,000, and the Note was issued to Labrys. The SPA includes customary representations, warranties and covenants by the Company and customary closing conditions. The SPA requires that the proceeds from the Transaction be used for business development and general working capital purposes, but not for repayment of debt owed to officers, directors or employees of the Company or their affiliates, the repayment of debt issued in corporate finance transactions, any loan to or investment in any other entity, or any loan to any officers, directors, employees or affiliates of the Company. The Note matures twelve months following the issue date, accrues a one-time interest charge of 12% on the principal amount at issuance, shall be paid $54,740 by February 4, 2026, and $9,123.33 by the 4 th day of each month thereafter, and is convertible following default into shares of the Company's common stock at the election of the holder at a conversion price equal to 71% of the lowest closing bid price during the 10 trading days prior to the conversion date; provided, however, that the holder may not convert the Note to the extent that such conversion would result in the holder's beneficial ownership of the Company's common stock being in ex

02. Unregistered Sales of Equity Securities

Item 3.02. Unregistered Sales of Equity Securities. The disclosure provided above in Item 1.01 above is incorporated by reference into this Item 3.02. The Note was sold in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, as there was no general solicitation, and the issuance did not involve a public offering. 2

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Securities Purchase Agreement, dated August 4, 2025, entered into between the Company and Labrys Fund II, L.P. * 10.2 Promissory Note, dated August 4, 2025, issued by the Company to Labrys Fund II, L.P. * 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document) * Filed herewith. 3 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Innovative MedTech, Inc. Date: August 7, 2025 By: /s/ Michael Jordan Friedman Michael Jordan Friedman President, Chief Executive Officer and Member of the Board of Directors 4

View Full Filing

View this 8-K filing on SEC EDGAR